Achieve Life Sciences (NASDAQ:ACHV) Issues Quarterly Earnings Results, Misses Estimates By $0.23 EPS
Achieve Life Sciences (NASDAQ:ACHV) posted its earnings results on Wednesday. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.23), Fidelity Earnings reports.
ACHV stock traded down $0.14 during mid-day trading on Friday, hitting $0.91. 243,100 shares of the stock were exchanged, compared to its average volume of 609,746. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.62 and a quick ratio of 3.62. The business has a fifty day moving average price of $1.58 and a 200 day moving average price of $2.41. Achieve Life Sciences has a 12 month low of $0.88 and a 12 month high of $4.63. The stock has a market capitalization of $9.88 million, a price-to-earnings ratio of -0.25 and a beta of 1.91.
Several equities research analysts have issued reports on ACHV shares. Maxim Group reaffirmed a “buy” rating and set a $6.00 price target on shares of Achieve Life Sciences in a research note on Tuesday, October 1st. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $20.00 price target on shares of Achieve Life Sciences in a research note on Friday, August 9th. Finally, ValuEngine raised Achieve Life Sciences from a “hold” rating to a “buy” rating in a research note on Friday.
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.
Read More: Average Daily Trade Volume Explained
Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.